Abstract：
:Plerixafor was recently approved by the US Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) to enhance stem cell mobilization for autologous transplant in patients with lymphoma and multiple myeloma. In this study, we present the first European compassionate use experience in mobilization failures, patients who are hardest to remobilize but were not included in registration trials. A total of 56 consecutive patients from 15 centers in Spain and the United Kingdom were included: age 60 (33-69) years; 29 men (32 with myeloma and 24 with lymphoma); 2 lines of previous chemotherapy (1-10); 73 previously failed mobilization attempts with G-CSF (28), chemotherapy plus G-CSF (43) or G-CSF plus SCF(2). Overall, 71% of patients reached ≥ 10 CD34+ cells per μL with plerixafor on day 5 after a 7.6-fold expansion from day 4. A total of 42 patients (75%) collected ≥ 2 × 10⁶, average 3.0 ± 1.7 (0.4-10.6) CD34+ cells per kg with plerixafor plus G-CSF. There were no severe drug-related adverse events. In all, 35 patients (63%) underwent transplant, receiving an average of 3.1±1.2 (1.9-7.7) × 10⁶ CD34+ cells per kg. All patients engrafted neutrophils (day 12; 13.4 ± 0.8; 8-30) and platelets (day 15; 18.5 ± 2.4; 8-33). In our experience, plerixafor offers an effective alternative to collect sufficient CD34+ cells for autologous SCT from patients who fail conventional mobilization methods, with good tolerance and a high success rate.
journal_name
Bone Marrow Transplantjournal_title
Bone marrow transplantationauthors
Duarte RF,Shaw BE,Marín P,Kottaridis P,Ortiz M,Morante C,Delgado J,Gayoso J,Goterriz R,Martínez-Chamorro C,Mateos-Mazón JJ,Ramírez C,de la Rubia J,Achtereekte H,Gandhi PJ,Douglas KW,Russell NHdoi
10.1038/bmt.2010.54subject
Has Abstractpub_date
2011-01-01 00:00:00pages
52-8issue
1eissn
0268-3369issn
1476-5365pii
bmt201054journal_volume
46pub_type
杂志文章abstract：:The role of autologous bone marrow transplantation in the treatment of malignant disease is currently being evaluated. The peripheral blood represents an alternative source of haemopoietic progenitors and the use of circulating rather than bone marrow stem cells permits autografting in patients with infiltrated bone m...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,评审
doi：
更新日期：1986-12-01 00:00:00
abstract：:The prognosis of adult patients with ALL remains unsatisfactory. AlloSCT is associated with a beneficial GVL response mediated by donor T cells. However, GVHD results in substantial mortality and long-term morbidity. T-cell depletion (TCD) of the graft reduces the severity of GVHD, but is associated with an increased ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2013.111
更新日期：2014-02-01 00:00:00
abstract：:Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has proven effective in adult T-cell leukemia/lymphoma (ATL) patients. To study the graft-versus-ATL (Gv-ATL) effects after allo-HSCT, we analyzed 21 ATL patients who had been treated at our hospital. Of these, 18 had acute-, 2 had lymphoma- and 1 had chro...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2008.39
更新日期：2008-06-01 00:00:00
abstract：SUMMARY:High-dose busulfan is an important component of myeloablative regimens. Variable drug exposure may occur following oral administration. Therefore, the use of intravenous busulfan has been advocated. Previous work has suggested a cumulative dosage of 16 mg/kg for haematopoietic transplantation in children less t...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1704209
更新日期：2003-10-01 00:00:00
abstract：:Current prophylaxis regimens do not provide satisfactory control of graft-versus-host disease (GVHD) in patients transplanted with unmodified marrow from an unrelated donor or from a related donor mismatched for more than one HLA antigen. Extensive T cell depletion of the donor marrow can eliminate the need for post-t...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,评审
doi：
更新日期：1990-11-01 00:00:00
abstract：:Two patients with high-risk acute myeloid leukemia (AML) whose bone marrow aspirates showed more than 25% blasts between 2 and 4 weeks after the first induction chemotherapy immediately received modified conditioning therapy with intravenous busulfan at 50% of the usual dose and fludarabine, before hematologic recover...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1702819
更新日期：2001-03-01 00:00:00
abstract：:One hundred patients with chronic myeloid leukemia (CML) submitted to bone marrow transplantation (BMT) were included in a cooperative cytogenetic study. Relapse (defined on the basis of hematological and cytogenetic findings) occurred in 24 (24%) patients at different intervals after BMT. In 18 of these patients (stu...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1988-09-01 00:00:00
abstract：:A patient with chronic myeloid leukemia (CML) who developed a disseminated infection by mycobacterium avium complex (MAC) was successfully treated with rifampin, ethambutol, isoniazid, cycloserin and ciprofloxacin. Diagnosis was proven by histologic examination of hepatic biopsy and culture of the liver biopsy materia...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1995-07-01 00:00:00
abstract：:Two hundred and ten bronchoalveolar lavage (BAL) samples were obtained from 50 patients 10 days before and on defined days after allogeneic bone marrow transplantation (BMT). The samples were examined for human cytomegalovirus (HCMV) and human herpesvirus-6 (HHV-6) by polymerase chain reaction (PCR). Fifteen patients ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1702569
更新日期：2000-09-01 00:00:00
abstract：:A male patient with CML received a BMT from his sister and developed chronic GVHD. The host-origin normal karyotype (46,XY) was identified for the first time in the 60th month after BMT. Detection of Y-chromosome-specific DNA in BM and peripheral blood (PB) showed that all BM samples obtained 6 months from BMT were po...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1993-07-01 00:00:00
abstract：:Lupus inhibitors have been reported in a number of pathologic states in which there is a disruption of normal immunoregulation. We report here the development of new lupus inhibitors following bone marrow transplantation. Retrospective analysis of 1292 patients undergoing transplantation at the University of Minnesota...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1995-02-01 00:00:00
abstract：:Children with high risk or relapsed acute lymphoblastic leukaemia (ALL) can benefit from allogeneic haematopoietic stem cell transplantation (SCT). To reduce transplantation-associated complications, the BFM study group, the IBFM study group and the PD-WP-EBMT initiated a prospective cooperative multicentre trail for ...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章,多中心研究
doi：10.1038/sj.bmt.1704835
更新日期：2005-03-01 00:00:00
abstract：:The aim of this study was to define factor(s) influencing fetal erythropoiesis following bone marrow transplantation. Thirty-one transplanted patients (14 males, 17 females) were studied. The underlying diseases were chronic myelogenous leukaemia (CML, 18 patients), acute myeloblastic leukaemia (AML, 7 patients) and a...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1994-11-01 00:00:00
abstract：:Post-transplant lymphoproliferative disorders (PTLD) are morphologically/clinically heterogeneous. The main goal of this study was to define the histogenesis of PTLD (B-cell phenotype, EBV-related) in seven pediatric patients after allogeneic T-cell-depleted bone marrow transplantation. Immunohistochemical stains usin...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1704395
更新日期：2004-02-01 00:00:00
abstract：:The use of hematopoietic stem cell transplantation or blood and marrow transplantation (BMT) is on the increase worldwide. With BMT's increasing utilization and increasing success, the number of BMT survivors in the United States alone is expected to surpass 500 000 by the year 2030. BMT survivors are susceptible to a...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,评审
doi：10.1038/bmt.2015.228
更新日期：2016-02-01 00:00:00
abstract：:Conditioning including total body/lymphoid irradiation is widely used to prevent graft rejection in patients with refractory severe aplastic anemia (SAA) undergoing hemopoietic cell transplantation (HCT) from alternative donors and or after graft manipulation. To reduce regimen-related toxicity we transplanted three c...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1704792
更新日期：2005-03-01 00:00:00
abstract：:Hematopoietic cell transplantation (HCT) following nonmyeloablative conditioning (NMSCT) may be associated with a reduced risk of infection compared to standard allogeneic HCT. We retrospectively analyzed incidence and risk factors of infection in 62 patients undergoing NMSCT with low-dose TBI +/- fludarabine and post...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1705255
更新日期：2006-02-01 00:00:00
abstract：:Among 145 consecutive patients undergoing bone marrow transplantation (BMT) for leukemia or aplastic anemia. 30 (21%) were found positive for hepatitis B surface antigen (HBsAg) in serum either before or after BMT. Their serologic profile and clinical outcome are described. Nine out of 30 patients were HBsAg positive ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1990-07-01 00:00:00
abstract：:Limiting dilution analysis was used to quantify the frequency of cytotoxic T cell precursors (CTLp) against minor histocompatibility (H) antigens induced by HLA-identical BMT. The development of CTLp was monitored serially in ten patients developing either acute (n = 3), acute and chronic (n = 4) or no (n = 3) GVHD. I...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1993-05-01 00:00:00
abstract：:Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with intermediate-risk AML, who...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2012.84
更新日期：2013-01-01 00:00:00
abstract：:Immunotherapy in the form of donor lymphocyte infusions in early-phase relapse might be advantageous as it induces a higher response, but this may be offset by increased toxicity, especially during the early period after transplantation. Among 45 consecutive patients receiving an allograft for CML, 13 patients were di...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章,随机对照试验
doi：10.1038/sj.bmt.1704386
更新日期：2004-03-01 00:00:00
abstract：:The physical and psychosocial consequences for patients undergoing blood SCT for the treatment of cancer and their families have been extensively documented. There has, however, been far less investigation into the psychosocial consequences for sibling donors who are both family members and undergoing an invasive medi...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章
doi：10.1038/bmt.2012.22
更新日期：2012-10-01 00:00:00
abstract：:We review here the functional and kinetic characteristics of highly purified hematopoietic CD34+ mobilized into peripheral blood (PB) by granulocyte colony-stimulating factor (G-CSF) with or without chemotherapy for autologous or allogeneic transplantation. Circulating CD34+ cells were evaluated for their colony-formi...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1998-12-01 00:00:00
abstract：:The aim of the present trial was to investigate the feasibility of high-dose therapy followed by autologous peripheral blood stem cell transplantation (PBSCT) as a component of front-line treatment in patients with disseminated intermediate- and high-grade non-Hodgkin's lymphoma (NHL) aged 61-65 years. From October 19...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1701272
更新日期：1998-06-01 00:00:00
abstract：:The use of cytokines following bone marrow transplantation has become an area of increasing controversy with specific regard to indication, efficacy and cost. This review will attempt to summarize cytokine data in both adult and pediatric transplantation. Indications for cytokines following transplantation will be pre...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,评审
doi：
更新日期：1996-12-01 00:00:00
abstract：:Outcomes in multiple myeloma (MM) have improved significantly with novel agent therapy and autologous stem cell transplantation (ASCT). ASCTs are typically planned as either tandem or a single transplant with additional stored PBSCs available for a second salvage transplant. To accommodate these strategies, many cente...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2015.13
更新日期：2015-05-01 00:00:00
abstract：:From May 1985 to July 1989, 76 patients with leukemia (30 acute myelogenous leukemia, 24 acute lymphoblastic leukemia and 22 chronic myeloid leukemia) were randomized to receive either cyclosporin (CSP) alone (n = 39) or CSP combined with methotrexate (CSP + MTX, n = 37) for graft-versus-host disease (GVHD) prophylaxi...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章,随机对照试验
doi：
更新日期：1990-08-01 00:00:00
abstract：:In this study, cytogenetic and molecular analyses were employed to assess the response to therapy in 29 chronic myeloid leukemia patients undergoing high dose chemotherapy followed by autologous stem cell infusion. Of these, 11 had previously achieved hematologic remission and cytogenetic improvement after alpha-2b in...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1990-10-01 00:00:00
abstract：:This survey on transplantation of hematopoietic stem cells from blood or bone marrow in Europe, the 10th in a series, reports the numbers of transplants performed in 1999 and concentrates on changes in indications and donor types. Members of the European Group for Blood and Marrow Transplantation and associated teams ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1702995
更新日期：2001-05-01 00:00:00
abstract：:The efficacy of posttransplant cyclophosphamide (PTCy) and antithymocyte globulin (ATG) in controlling GVHD has been previously reported. We aim to study the safety and efficacy of the use of dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning regimen allo-HSCT in 270 patients w...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/s41409-020-0813-9
更新日期：2020-09-01 00:00:00
